BLCO vs GSK · rev $5.10B vs P/E 13, $103.31B cap
Bausch + Lomb Corp (BLCO) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Bausch + Lomb Corp (BLCO) is a medical instruments & supplies company listed on NYSE.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported BLCO revenue for 2025-12-31 was $5.10B. Net income was -$360.0M. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. BLCO currently screens at market cap $5.38B.
GSK does not have a complete income-statement cache yet.
BLCO currently screens at market cap $5.38B. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the BLCO and GSK stock pages for the full models.
Not investment advice.